VSViktoryia Sidarovich

Viktoryia Sidarovich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Viktoryia Sidarovich has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3

  • Open Access

    Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Neuroblastoma (NB) is an aggressive childhood tumor, with high-risk cases having a 5-year overall survival probability of approximately 50%. The multimodal therapeutic approach for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-consolidation phase as an antiproliferation and prodifferentiation agent to minimize residual disease and prevent relapse. Through small-molecule screening, we identified isorhamnetin (ISR) as a synergistic compound with 13cRA in inhibiting up to 80% of NB cell viability. The synergistic effect was accompanied by a marked increase in the expression of the adrenergic receptor α1B (ADRA1B) gene. Genetic knockout of ADRA1B or its specific blockade using α1/α1B adrenergic antagonists led to selective sensitization of MYCN-amplified NB cells to cell viability reduction and neural differentiation induced by 13cRA, thus mimicking ISR activity. Administration of doxazosin, a safe α1-antagonist used in pediatric patients, in combination with 13cRA in NB xenografted mice exerted marked control of tumor growth, whereas each drug alone was ineffective. Overall, this study identified the α1B adrenergic receptor as a pharmacologic target in NB, supporting the evaluation of adding α1-antagonists to the post-consolidation therapy of NB to more efficiently control residual disease.Significance:Targeting α-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote differentiation of neuroblastoma, revealing a combinatorial approach for more effective management of the disease and prevention of relapse.

  • Open Access

    Data from Alpha-1 adrenergic antagonists sensitize neuroblastoma to therapeutic differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Neuroblastoma (NB) is an aggressive childhood tumor, with high-risk cases having a 5-year overall survival probability of approximately 50%. The multimodal therapeutic approach for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-consolidation phase as an anti-proliferation and pro-differentiation agent to minimize residual disease and prevent relapse. Through small molecule screening, we identified isorhamnetin (ISR) as a synergistic compound with 13cRA in inhibiting up to 80% of NB cell viability. The synergistic effect was accompanied by a marked increase in the expression of the adrenergic receptor α1B (ADRA1B) gene. Genetic knockout of ADRA1B or its specific blockade using ɑ1/ɑ1B adrenergic antagonists led to selective sensitization of MYCN-amplified NB cells to cell viability reduction and neural differentiation induced by 13cRA, thus mimicking ISR activity. Administration of doxazosin, a safe α1-antagonist used in pediatric patients, in combination with 13cRA in NB xenografted mice exerted marked control of tumor growth, while each drug alone was ineffective. Overall, this study identified the α1B adrenergic receptor as a pharmacological target in NB, supporting the evaluation of adding α1-antagonists to the post-consolidation therapy of NB to more efficiently control residual disease.

  • Open Access

    Supplementary Data from Alpha-1 adrenergic antagonists sensitize neuroblastoma to therapeutic differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3

  • Open Access

    Supplementary Data from Alpha-1 adrenergic antagonists sensitize neuroblastoma to therapeutic differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3

  • Open Access

    EGCG Disrupts the LIN28B/Let-7 Interaction and Reduces Neuroblastoma Aggressiveness

    by Simona Cocchi, Valentina Greco, Viktoryia Sidarovich, Jacopo Vigna, Francesca Broso, Diana Corallo, Jacopo Zasso, Angela Re, Emanuele Filiberto Rosatti, Sara Longhi, et al.

    Neuroblastoma (NB) is the most commonly diagnosed extracranial solid tumor in children, accounting for 15% of all childhood cancer deaths. Although the 5-year survival rate of patients with a high-risk disease has increased in recent decades, NB remains a challenge in pediatric oncology, and the identification of novel potential therapeutic targets and agents is an urgent clinical need. The RNA-binding protein LIN28B has been identified as an oncogene in NB and is associated with a poor prognosis. Given that LIN28B acts by negatively regulating the biogenesis of the tumor suppressor let-7 miRNAs, we reasoned that selective interference with the LIN28B/let-7 miRNA interaction would increase let-7 miRNA levels, ultimately leading to reduced NB aggressiveness. Here, we selected (−)-epigallocatechin 3-gallate (EGCG) out of 4959 molecules screened as the molecule with the best inhibitory activity on LIN28B/let-7 miRNA interaction and showed that treatment with PLC/PLGA-PEG nanoparticles containing EGCG (EGCG-NPs) led to an increase in mature let-7 miRNAs and a consequent inhibition of NB cell growth. In addition, EGCG-NP pretreatment reduced the tumorigenic potential of NB cells in vivo. These experiments suggest that the LIN28B/let-7 miRNA axis is a good therapeutic target in NB and that EGCG, which can interfere with this interaction, deserves further preclinical evaluation.


  • Open Access

    Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Neuroblastoma (NB) is an aggressive childhood tumor, with high-risk cases having a 5-year overall survival probability of approximately 50%. The multimodal therapeutic approach for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-consolidation phase as an antiproliferation and prodifferentiation agent to minimize residual disease and prevent relapse. Through small-molecule screening, we identified isorhamnetin (ISR) as a synergistic compound with 13cRA in inhibiting up to 80% of NB cell viability. The synergistic effect was accompanied by a marked increase in the expression of the adrenergic receptor α1B (ADRA1B) gene. Genetic knockout of ADRA1B or its specific blockade using α1/α1B adrenergic antagonists led to selective sensitization of MYCN-amplified NB cells to cell viability reduction and neural differentiation induced by 13cRA, thus mimicking ISR activity. Administration of doxazosin, a safe α1-antagonist used in pediatric patients, in combination with 13cRA in NB xenografted mice exerted marked control of tumor growth, whereas each drug alone was ineffective. Overall, this study identified the α1B adrenergic receptor as a pharmacologic target in NB, supporting the evaluation of adding α1-antagonists to the post-consolidation therapy of NB to more efficiently control residual disease.Significance:Targeting α-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote differentiation of neuroblastoma, revealing a combinatorial approach for more effective management of the disease and prevention of relapse.

  • Open Access

    Supplementary Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3

  • Open Access

    Supplementary Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3

  • Open Access

    Data from Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation

    by Francesca Broso, Pamela Gatto, Viktoryia Sidarovich, Chiara Ambrosini, Veronica De Sanctis, Roberto Bertorelli, Elena Zaccheroni, Benedetta Ricci, Eliana Destefanis, Sara Longhi, et al.

    Neuroblastoma (NB) is an aggressive childhood tumor, with high-risk cases having a 5-year overall survival probability of approximately 50%. The multimodal therapeutic approach for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-consolidation phase as an antiproliferation and prodifferentiation agent to minimize residual disease and prevent relapse. Through small-molecule screening, we identified isorhamnetin (ISR) as a synergistic compound with 13cRA in inhibiting up to 80% of NB cell viability. The synergistic effect was accompanied by a marked increase in the expression of the adrenergic receptor α1B (ADRA1B) gene. Genetic knockout of ADRA1B or its specific blockade using α1/α1B adrenergic antagonists led to selective sensitization of MYCN-amplified NB cells to cell viability reduction and neural differentiation induced by 13cRA, thus mimicking ISR activity. Administration of doxazosin, a safe α1-antagonist used in pediatric patients, in combination with 13cRA in NB xenografted mice exerted marked control of tumor growth, whereas each drug alone was ineffective. Overall, this study identified the α1B adrenergic receptor as a pharmacologic target in NB, supporting the evaluation of adding α1-antagonists to the post-consolidation therapy of NB to more efficiently control residual disease.Significance:Targeting α-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote differentiation of neuroblastoma, revealing a combinatorial approach for more effective management of the disease and prevention of relapse.